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• Triamcinolone acetonide is a corticosteroid used in the treatment of
macular edema of different etiologies.
• Blood retinal barrier action vascular permeability.
• Secondary Effects: ocular hypertension/glaucoma; cataract.
Non-Vitrectomized
Eyes
Half-life Time: 18,6 days
Vitreous Detection: 11 
weeks
Vitrectomized Eyes Half-life Time: 3,2 days Duration of action ?
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Material and Methods































14 Right Eye (60,9%)
9 Left Eye (39,1%)
Age 59,05± 8,63 years
Causes
• DME 82,6% (19 eyes)
• RD 8,7% (2)
• Trauma 4,3% (1)
• Lamellar Hole and Macular Schisis 4,3% (1)
Pseudophakic 23 Eyes
PPV-IVTA time 13,3± 8,28 months
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Visual Acuity and IOP Results
Previous Visual Acuity: 0,41
Post Visual Acuity: 0,55
p=>0.05 (t-paired test)
Previous IOP: 16,9± 2,0 mmHg








TA effect time: 0-17 months
Average: 3,61±3,34 months
11 weeks in non-vitrectomized eyes
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Conclusion
Macular edema is an important cause of visual loss.
Triamcinolone is a therapeutic option acting by decreasing 
vascular permeability and anti-inflammatory action.
Vitrectomized Eyes should have a shorter duration of effect 
than non-vitrectomized eyes.
Macular edema is highly responsive to triamcinolone.
IOP increase is an important side-effect.
Average TA effect is 3,61±3,34 months  similar results than 
in non-vitrectomized eyes.
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Why do you think you can get such a long 
duration of effect in these patients?
• Vitreous as a pathway of drug delivery and clearance in eye.
• There are few studies comparing TA concentration in vitrectomized and
nonvitrectomized eyes.
• No studies in human eyes.
• Logarithmical plotting shows that triamcinolone (0.3 mg) was eliminated
1.84 times quickly in vitrectomized + lensectomy rabbit eyes (China and
Kim et al. Investigative Ophthalmology & Visual Science 2004. ARVO).
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Why do you think you can get such a long 
duration of effect in these patients?
• Anti-VEGF
 No significant differences between pharmacokinetics properties of ranibizumab in
vitrectomized and nonvitrectomized rabbit eyes. (Ahn S., Ahn J. et al. in IOVS 2014 Jan)
 No BVCZ significant difference between pharmacokinetics properties in vitrectomized
and nonvitrectomized eyes. (Ahn J. Kim H. et al. un Journal of Ocular Pharmacology and
Therapeuthics, 2013 Jan)
 No lensectomy was performed which is more similar than regular PPV procedure.
 Centrifuge Concentrated Triamcinolone in nonvitrectomized eyes: 8.3±4.0 months
(Ober et al. in Retina, 2013)
 Phase 1 DRAW study: compares aflibercept in wet-AMD vitrectomized and non-
vitrectomized eyes.
• What about the RPE function?
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Do you feel there is a difference in the incidence 
of side-effects such as intraocular pressure?
• Steroid-induced glaucoma is a well-known side-effect of steroid
administration.
• Vitrectomy surgery itself has been related with open-angle glaucoma,
particularly in nonphakic eyes.
• Vitrectomized eyes: dispersion of triamcinolone crystals into the anterior
chamber (pseudohypopion) blocking trabecular spaces.
• Ocular hypertension after TA with vitrectomy and phacoemulsification is
reported in Parke and Sisk et al. in Clinical Ophthalmology 2012.
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Do you feel there is a difference in the incidence 
of side-effects such as intraocular pressure?
• Management:
 Drug discontinuation
 Topical IOP-lowering agents
 Oral carbonic-anhydrase inhibitor
 Filtering surgery
 Reported rates of IOP elevation: 20-80%.
 We had to stop our treatment in 4/23 eyes (17,4%) and 5/23 (21,7%) eyes
were controlled with one eye drop.
 IOP elevation in 39,1% of our cases.
